Risk of renal impairment after treatment with ibandronate versus zoledronic acid: A retrospective medical records review

Supportive Care in Cancer

Volumn 17, Issue 6, 2009, Pages 719-725

  Diel, Ingo J ^a   Weide, Rudolf ^b   Köppler, Hubert ^b   Antràs, Lucia ^c   Smith, Michael ^c   Green, Jesse ^d   Wintfeld, Neil ^d   Neary, Maureen ^e   Duh, Mei Sheng ^c  

^a Ctr fur Ganzheitliche Gynakol   (Germany)

^b Praxisklinik fur Hamatologie und Onkologie   (Germany)

^c ANALYSIS GROUP   (United States)

^d HOFFMANN LA ROCHE INC   (United States)

^e GLAXOSMITHKLINE   (United States)

Author keywords

Creatinine clearance; Ibandronate; Medical records; Renal impairment; Zoledronic acid

Indexed keywords

CREATININE; IBANDRONIC ACID; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CENTER; COMORBIDITY; CONTROLLED STUDY; FEMALE; GERMANY; GROUPS BY AGE; HAZARD RATIO; HUMAN; INCIDENCE; KIDNEY DISEASE; KIDNEY FUNCTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CANCER CARE FACILITIES; CREATININE; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; KIDNEY FAILURE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 67349225634     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-008-0553-7     Document Type: Article

References (32)

1. J Berenson R Hirschberg 2004 Safety and convenience of a 15-minute infusion of zoledronic acid Oncologist 9 319 329 (Pubitemid 38756880)
2. R Bergner IJ Diel D Henrich M Hoffmann M Uppenkamp 2006 Differences in nephrotoxicity of intravenous bisphosphonates for the treatment of malignancy-related bone disease Onkologie 29 534 540 (Pubitemid 44631677)
3. JJ Body IJ Diel MR Lichinitser 2003 Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases Ann Oncol 14 1399 1405 (Pubitemid 37185286)
4. JJ Body IJ Diel M Lichinitzer 2004 Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies Br J Cancer 90 1133 1137 (Pubitemid 38496803)
5. JJ Body IJ Diel D Tripathy B Bergström 2006 Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results Eur J Cancer Care (Engl) 15 299 302
6. JJ Body M Lichinitser S Tjulandin B Bergström 2006 Oral ibandronate and intravenous zoledronic acid in metastatic breast cancer patients: comparative bone turnover marker and safety data [abstract 68] Bone 38 3 Suppl.1 S69 (Pubitemid 43098408)
7. JT Chang L Green J Beitz 2003 Renal failure with the use of zoledronic acid N Engl J Med 349 1676 1679
8. B Chern D Joseph D Joshua 2004 Bisphosphonate infusions: patient preference, safety and clinic use Support Care Cancer 12 463 466 (Pubitemid 38797103)
9. JA Cramer MM Amonkar A Hebborn R Altman 2005 Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis Curr Med Res Opin 21 1453 1460 (Pubitemid 41368578)
10. IJ Diel R Weide H Köppler 2006 Renal impairment in cancer patients following zoledronic acid or ibandronate treatment [abstract 1002P] Ann Oncol 17 Suppl.9 78
11. R Eastell P Garnero B Vrijens 2006 Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the IMPACT study Calcif Tissue Int 72 408
12. A Ezra B Golomb 2000 Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption Adv Drug Deliv Rev 42 175 195 (Pubitemid 30645777)
13. JR Green K Müller KA Jaeggi 1994 Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound J Bone Miner Res 9 745 751 (Pubitemid 24130477)
14. A Heidenreich C Ohlmann A Olbert P Hegele 2003 High-dose ibandronate is effective and well tolerated in the treatment of pain and hypercalcaemia due to metastatic urologic cancer Eur J Cancer 1 Suppl.5 S270
15. D Henrich R Bergner M Hoffman 2005 Open-label study of ibandronate in elderly myeloma patients with pre-existing renal deterioration [abstract 3459] Blood 106 11
16. KB Johnson P Gable EM Kaine 2003 Significant deterioration in renal function with the new bisphosphonate zoledronic acid [abstract 2968] J Clin Oncol 22 Suppl. 738
17. B Kristensen B Ejlertsen M Groenvold 1999 Oral clodronate in breast cancer patients with bone metastases: a randomized study J Intern Med 246 67 64 (Pubitemid 29327354)
18. AS Levey JP Bosch JB Lewis T Greene N Rogers D Roth 1999 A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group Ann Intern Med 130 461 470
19. NV Lyubimova NE Kushlinsky K Lichinister MR Schlosser 2003 Renal safety of intravenous ibandronic acid in breast cancer patients with metastatic bone disease Clin Drug Invest 23 707 716 (Pubitemid 37373792)
20. P Major A Lortholary J Hon 2001 Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials J Clin Oncol 19 558 567 (Pubitemid 32112871)
21. I Mancini JJ Dumon JC Body 2004 Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study J Clin Oncol 22 3587 3592 (Pubitemid 41103666)
22. GS Markowitz PL Fine JI Stack 2003 Toxic acute tubular necrosis following treatment with zoledronate (Zometa) Kidney Int 64 281 289 (Pubitemid 36714182)
23. S Mazj SM Lichtman 2004 Renal dysfunction associated with bisphosphonate use: retrospective analysis of 293 patients with respect to age and other clinical characteristics [abstract 8039] J Clin Oncol 22 Suppl. 735
24. RC Mühlbauer F Bauss R Schenk 1991 BM 21.0955, a potent new bisphosphonate to inhibit bone resorption J Bone Miner Res 6 1003 1011
25. A Munier V Gras M Andrejak 2005 Zoledronic acid and renal toxicity: data from French adverse effect reporting database Ann Pharmacother 39 1194 1197 (Pubitemid 40943168)
26. T Pfister E Atzpodien F Bauss 2003 The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats Toxicology 191 159 167 (Pubitemid 37329461)
27. T Pfister E Atzpodien B Bohrmann F Bauss 2005 Acute renal effects of intravenous bisphosphonates in the rat Basic Clin Pharmacol Toxicol 97 374 381 (Pubitemid 43028785)
28. JY Reginster V Rabenda 2006 Patient preference in the management of postmenopausal osteoporosis with bisphosphonates Clin Interv Aging 1 415 423
29. LS Rosen D Gordon M Kaminski 2003 Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial Cancer 98 1735 1744 (Pubitemid 37238631)
30. H Taggart MA Bolognese R Lindsay 2002 Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials Mayo Clin Proc 77 262 270 (Pubitemid 34177602)
31. R Thadhani M Pascual JV Bonventre 1996 Acute renal failure N Engl J Med 334 1448 1460 (Pubitemid 126590563)
32. von Moos R, Caspar CB, Angst R et al (2006) Renal safety of intravenous ibandronate 6 mg infused over 15 minutes or 60 minutes in patients with breast cancer and bone metastases [abstract 1078]